ROCKVILLE, MD – November 9, 2015 – Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that the Company has received an accelerated second tranche from its previously announced Series B financing and expanded its investor syndicate with gross proceeds of up to $6.75 million. Brace Pharma Capital led the financing.

For more information: Click Here